Dual‐target inhibitors, such as IDO/TDO inhibitors and IDO inhibitors targeting other pathways, have shown potential to enhance tumor treatment efficacy by achieving synergistic effects between two targets, avoiding drug interactions and metabolic disparities.288, 289, 290, 291. This evidence concerns the gene IDO1 and neoplasm.